HCFC1
Basic information
Region (hg38): X:153947557-153971818
Previous symbols: [ "HFC1", "MRX3" ]
Links
Phenotypes
GenCC
Source:
- methylmalonic acidemia with homocystinuria, type cblX (Definitive), mode of inheritance: XLR
- methylmalonic acidemia with homocystinuria, type cblX (Moderate), mode of inheritance: XL
- non-syndromic X-linked intellectual disability (Supportive), mode of inheritance: XL
- methylmalonic acidemia with homocystinuria, type cblX (Supportive), mode of inheritance: XL
- X-linked intellectual disability (Definitive), mode of inheritance: XL
- methylmalonic acidemia with homocystinuria, type cblX (Definitive), mode of inheritance: XL
- methylmalonic acidemia with homocystinuria, type cblX (Strong), mode of inheritance: XL
- X-linked intellectual disability (Definitive), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Methylmalonic aciduria and homocysteinemia, cblX type | XL | Biochemical | Medical interventions (eg, cofactor therapy with injectable hydroxycobalamin) and dietary management (eg, high-calorie, low protein diet and avoidance of fasting, with measures taken to avoid/treat decompensation) may be to beneficial in both acute and chronic states | Biochemical; Neurologic | 24011988 |
ClinVar
This is a list of variants' phenotypes submitted to
- Methylmalonic acidemia with homocystinuria, type cblX (2 variants)
- Disorders of Intracellular Cobalamin Metabolism (1 variants)
- not provided (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HCFC1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 453 | 136 | 593 | |||
missense | 212 | 79 | 14 | 310 | ||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 10 | 14 | ||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 9 | 40 | 4 | 53 | ||
non coding | 184 | 49 | 233 | |||
Total | 4 | 2 | 227 | 719 | 201 |
Variants in HCFC1
This is a list of pathogenic ClinVar variants found in the HCFC1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-153949054-G-A | Benign (Aug 14, 2018) | |||
X-153949297-C-T | Likely benign (May 25, 2021) | |||
X-153949359-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Benign (Oct 04, 2023) | ||
X-153949361-C-T | Methylmalonic acidemia with homocystinuria, type cblX | Uncertain significance (Sep 04, 2022) | ||
X-153949365-A-G | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Nov 20, 2023) | ||
X-153949366-G-C | Uncertain significance (Oct 01, 2021) | |||
X-153949381-G-C | Uncertain significance (Feb 01, 2022) | |||
X-153949386-C-A | Methylmalonic acidemia with homocystinuria, type cblX | Uncertain significance (Mar 17, 2021) | ||
X-153949390-G-A | Likely benign (May 17, 2018) | |||
X-153949391-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Benign (Jan 22, 2024) | ||
X-153949394-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Benign (Dec 30, 2023) | ||
X-153949402-A-G | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Sep 15, 2023) | ||
X-153949406-A-G | Methylmalonic acidemia with homocystinuria, type cblX | Benign (Jan 29, 2024) | ||
X-153949533-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Benign (Dec 14, 2023) | ||
X-153949534-A-G | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Mar 27, 2023) | ||
X-153949538-G-C | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Oct 17, 2023) | ||
X-153949539-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Jan 26, 2023) | ||
X-153949540-G-C | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Aug 14, 2021) | ||
X-153949542-T-C | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Jun 12, 2023) | ||
X-153949553-A-G | Uncertain significance (Jan 20, 2023) | |||
X-153949560-G-A | Uncertain significance (Dec 15, 2022) | |||
X-153949570-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (Jan 24, 2023) | ||
X-153949575-G-A | Pathogenic (Jul 01, 2021) | |||
X-153949579-G-A | Methylmalonic acidemia with homocystinuria, type cblX | Conflicting classifications of pathogenicity (Nov 02, 2021) | ||
X-153949582-G-C | Methylmalonic acidemia with homocystinuria, type cblX | Likely benign (May 28, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HCFC1 | protein_coding | protein_coding | ENST00000310441 | 26 | 24255 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.86e-8 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 5.63 | 419 | 893 | 0.469 | 0.0000774 | 12925 |
Missense in Polyphen | 218 | 598.05 | 0.36452 | 8637 | ||
Synonymous | -2.08 | 477 | 423 | 1.13 | 0.0000421 | 4642 |
Loss of Function | 6.50 | 0 | 49.2 | 0.00 | 0.00000349 | 769 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in control of the cell cycle (PubMed:10629049, PubMed:10779346, PubMed:15190068, PubMed:16624878, PubMed:23629655). Also antagonizes transactivation by ZBTB17 and GABP2; represses ZBTB17 activation of the p15(INK4b) promoter and inhibits its ability to recruit p300 (PubMed:10675337, PubMed:12244100). Coactivator for EGR2 and GABP2 (PubMed:12244100, PubMed:14532282). Tethers the chromatin modifying Set1/Ash2 histone H3 'Lys-4' methyltransferase (H3K4me) and Sin3 histone deacetylase (HDAC) complexes (involved in the activation and repression of transcription, respectively) together (PubMed:12670868). Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1 (PubMed:20200153). As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues (PubMed:20018852). Recruits KMT2E/MLL5 to E2F1 responsive promoters promoting transcriptional activation and thereby facilitates G1 to S phase transition (PubMed:23629655). {ECO:0000269|PubMed:10629049, ECO:0000269|PubMed:10675337, ECO:0000269|PubMed:10779346, ECO:0000269|PubMed:12244100, ECO:0000269|PubMed:12670868, ECO:0000269|PubMed:14532282, ECO:0000269|PubMed:15190068, ECO:0000269|PubMed:16624878, ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:20200153, ECO:0000269|PubMed:23629655}.;
- Disease
- DISEASE: Mental retardation, X-linked 3 (MRX3) [MIM:309541]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non- syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:23000143}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Herpes simplex infection - Homo sapiens (human);Mitochondrial Gene Expression;Post-translational protein modification;Metabolism of proteins;Chromatin modifying enzymes;HATs acetylate histones;UCH proteinases;Deubiquitination;Chromatin organization;Transcriptional activation of mitochondrial biogenesis;Mitochondrial biogenesis;Organelle biogenesis and maintenance
(Consensus)
Recessive Scores
- pRec
- 0.158
Intolerance Scores
- loftool
- 0.00303
- rvis_EVS
- -1.46
- rvis_percentile_EVS
- 3.86
Haploinsufficiency Scores
- pHI
- 0.358
- hipred
- Y
- hipred_score
- 0.831
- ghis
- 0.560
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.833
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hcfc1
- Phenotype
- embryo phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; cellular phenotype;
Zebrafish Information Network
- Gene name
- hcfc1b
- Affected structure
- neuronal stem cell
- Phenotype tag
- abnormal
- Phenotype quality
- disrupted
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;blastocyst hatching;regulation of transcription, DNA-templated;mitochondrion organization;cell cycle;positive regulation of gene expression;protein deubiquitination;release from viral latency;regulation of protein complex assembly;histone H4-K5 acetylation;histone H4-K8 acetylation;histone H4-K16 acetylation;positive regulation of cell cycle;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;protein stabilization;cellular response to organic cyclic compound
- Cellular component
- histone acetyltransferase complex;nucleus;nucleoplasm;Ada2/Gcn5/Ada3 transcription activator complex;cytoplasm;membrane;axon;dendrite;protein-containing complex;neuronal cell body;Set1C/COMPASS complex;SAGA-type complex;MLL1 complex
- Molecular function
- DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;transcription coactivator activity;protein binding;protein binding, bridging;activating transcription factor binding;identical protein binding;histone acetyltransferase activity (H4-K5 specific);histone acetyltransferase activity (H4-K8 specific);cadherin binding;histone acetyltransferase activity (H4-K16 specific);sequence-specific double-stranded DNA binding